A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Public ClinicalTrials.gov record NCT02092922. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The AfFIRM Study is a Phase 2 study during which patients with advanced multiple myeloma will receive single-agent investigational study drug filanesib (ARRY-520). Patients will be followed to determine the effectiveness of filanesib in treating myeloma. Approximately 160 patients from North America and Europe will be enrolled in this study. Eligible patients will have received at least two prior lines of therapy; have received prior bortezomib and lenalidomide; and have disease refractory to carfilzomib and/or pomalidomide.
Study identification
- NCT ID
- NCT02092922
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 154 participants
Conditions and interventions
Conditions
Interventions
- Filanesib, KSP (Eg5) inhibitor; intravenous Drug
- Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2014 (Actual)
- Primary completion
- Jul 2016 (Actual)
- Completion
- Sep 5, 2017 (Actual)
- Last update posted
- Oct 19, 2020
2014 – 2017
United States locations
- U.S. sites
- 29
- U.S. states
- 21
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UAB Comprehensive Cancer Center | Birmingham | Alabama | 35249 | — |
| City of Hope | Duarte | California | 91010 | — |
| University of California, San Francisco Medical Center | San Francisco | California | 94143 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| Colorado Blood Cancer Institute | Denver | Colorado | 80218 | — |
| Yale Comprehensive Cancer Center | New Haven | Connecticut | 06510 | — |
| Emory University, Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| Decatur Memorial Hospital | Decatur | Illinois | 62526 | — |
| University of Kansas Cancer Center and Medical Pavilion | Westwood | Kansas | 66205 | — |
| University of Kentucky | Lexington | Kentucky | 40536 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40202 | — |
| Center for Cancer and Blood Disorders | Bethesda | Maryland | 20817 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Washington University in St. Louis | St Louis | Missouri | 63130 | — |
| Nebraska Hematology Oncology, P.C. | Lincoln | Nebraska | 68506 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89169 | — |
| Mount Sinai Medical Center | New York | New York | 10029 | — |
| NY Presbyterian - Weill Cornell Medical Center | New York | New York | 10065 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Duke Cancer Center | Durham | North Carolina | 27710 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| UT Southwestern Medical Center | Dallas | Texas | 75390 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| Cancer Care Northwest | Spokane Valley | Washington | 99216 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02092922, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 19, 2020 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02092922 live on ClinicalTrials.gov.